PARP Inhibitors and Ovarian Cancer
8th December 2016: 7:00pm - 8:00pm AEDT
During this webinar Professor Jonathan Ledermann will share with us his extensive expertise in the area of PARP inhibitors and ovarian cancer.
Kristin Young lives with ovarian cancer, in this webinar she will share her experience with participating in the clinical trials for Olaparib.
|Jonathan Ledermann is Professor of Medical Oncology at UCL Cancer Institute and a consultant in medical oncology at UCL Hospitals, working in the Gynaecological Cancer Centre. He is the Clinical Director of the UCL Cancer Institute and Director of the Cancer Research UK and UCL Cancer Trials Centre, one of the national cancer trials Centres in the UK. He trained in medical oncology and general internal medicine and was a Clinical Research Fellow at the Charing Cross Hospital, London and a visiting Fellow at the Princess Margaret Hospital, Toronto and Ontario Cancer Institute. In 1990 he joined the Department of Oncology at University College London,His principal area of clinical practice and research is in gynaecological cancers. He has led many national and international clinical trials in ovarian cancer. He is a member of the ESMO Faculty and on the council of ESGO (European Society of Gynaecological Oncology) and the British Gynaecological Cancer Society (BGCS). He has previously served on the Council for the IGCS (International Gynaecologic Cancer Society) and is the past-chair of the NCRI Gynaecological Cancer Studies Group. He is the chair of the Rare Tumours subgroup of the Gynaecological Cancer Inter Group (GCIG). For many years he was a member Expert Advisory Groups for Oncology at the MHRA (Medicines and Health Regulatory Authority) and the EMA (European Medicines Agency). He is on the editorial board of three cancer journals and has published research papers, textbooks and educational chapters on many aspects of Gynaecological Cancer. He has lectured in many countries on his research and clinical experience. |
Kristin Young an ambassador for OCA was diagnosed with Stage IIIC ovarian cancer in 2009. After surgery and chemotherapy she started her first clinical trial for maintenance with an anti-angiogenesis agent. She was also found to have the BRCA2 gene fault. After a good remission she relapsed in early 2014, and after more surgery and chemotherapy Kristin started on the PARP Inhibitor Olaparib clinical trial which she is still currently on.
For technical assistance, please email Redback Support or call 1800 733 416.
Your personal information will be collected for the purpose of this webinar only. Please contact the organisation hosting this event should you require details on your privacy rights.